Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo

Blood

Volumn 117, Issue 15, 2011, Pages 3974-3982

  Margaritis, Paris ^a,b   Roy, Elise ^a   Faella, Armida ^a   Downey, Harre D ^a   Ivanciu, Lacramioara ^a   Pavani, Giulia ^a   Zhou, Shangzhen ^a   Bunte, Ralph M ^c   High, Katherine A ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 9; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INACTIVATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; GENE TRANSFER; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN VARIANT; PROTHROMBIN TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79954616699     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-309732     Document Type: Article

References (43)

1. Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol. 2007;14(3):225-229. (Pubitemid 46597607)
2. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001;38(4 Suppl 12):43-47. (Pubitemid 33130036)
3. Weimer T, Wormsbacher W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99(4):659-667. (Pubitemid 351694221)
4. Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia. 2008.
5. Harvey SB, Stone MD, Martinez MB, Nelsestuen GL. Mutagenesis of the gamma-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J Biol Chem. 2003;278(10):8363-8369. (Pubitemid 36800585)
6. Nelsestuen GL, Stone M, Martinez MB, Harvey SB, Foster D, Kisiel W. Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusionlimited reaction. J Biol Chem. 2001;276(43):39825-39831.
7. Persson E, Bak H, Ostergaard A, Olsen OH. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J. 2004;379(Pt 2):497-503. (Pubitemid 38570123)
8. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A. 2001;98(24):13583-13588. (Pubitemid 33115941)
9. Moss J, Scharling B, Ezban M, Sorensen TM. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost. 2008.
10. Petersen LC, Norby PL, Branner S, et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res. 2005;116(1):75-85. (Pubitemid 40546328)
11. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost. 2009.
12. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615-3620. (Pubitemid 37409379)
13. Aljamali MN, Margaritis P, Schlachterman A, et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest. 2008;118(5):1825-1834. (Pubitemid 351632385)
14. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004;113(7):1025-1031. (Pubitemid 38544124)
15. Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. 2009;113(16):3682- 3689.
16. Wang L, Wang H, Bell P, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther. 2010;18(1):118-125.
17. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006;108(1):107-115. (Pubitemid 43990618)
18. Sabatino DE, Lange AM, Altynova ES, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther. 2011;19(3):442-449.
19. Wang L, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liverdirected gene therapy. Blood. 2005;105(8):3079-3086.
20. Toso R, Bernardi F, Tidd T, et al. Factor VII mutant V154G models a zymogen-like form of factor VIIa. Biochem J. 2003;369(Pt 3):563-571. (Pubitemid 36246239)
21. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and-dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266(4):2158-2166. (Pubitemid 21909043)
22. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
23. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966. (Pubitemid 27484049)
24. Tai SJ, Herzog RW, Margaritis P, et al. A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. J Thromb Haemost. 2008;6(2):339-345.
25. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4(3):201-210. (Pubitemid 32851283)
26. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22(2):195-201. (Pubitemid 43205406)
27. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009;37:D387-392.
28. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL:An automated protein homology-modeling server. Nucleic Acids Res. 2003;31(13):3381-3385. (Pubitemid 37442164)
29. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-2723. (Pubitemid 28059943)
30. Persson E, Olsen OH. Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. Eur J Biochem. 2002;269(23):5950-5955. (Pubitemid 35425592)
31. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996;380(6569):41-46. (Pubitemid 26076234)
32. Nicolaisen EM, Thim L, Jacobsen JK, et al. FVIIa derivatives obtained by autolytic and controlled cathepsin G mediated cleavage. FEBS Lett. 1993;317(3):245-249. (Pubitemid 23045798)
33. Toso R, Pinotti M, High KA, Pollak ES, Bernardi F. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. Biochem J. 2002;363(Pt 2):411-416. (Pubitemid 34415779)
34. Hedner U. History of rFVIIa therapy. Thromb Res. 2010;125(Suppl 1):S4-S6.
35. Russell KE, Olsen EH, Raymer RA, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102(13):4393-4398. (Pubitemid 37494100)
36. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347. (Pubitemid 43355084)
37. Mingozzi F, Maus MV, Hui DJ, et al. CD8 (+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-422. (Pubitemid 46559826)
38. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913. (Pubitemid 47288949)
39. Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia. 2011;17(1):e172-e182. doi: 10.1111/j.1365-2516.2010.02352.x.
40. Gopalakrishnan R, Hedner U, Ghosh S, et al. Biodistribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost. 2010;8(2):301-310.
41. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5(7):1403-1408. (Pubitemid 46965368)
42. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671-1675.
43. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 2005;105(6):2316-2323. (Pubitemid 40387025)